Collegium Pharmaceutical price to free cash flow COLL

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 2.3×
8-year median: 5.4×
Against its 8-year history: 1st; percentile: 0 is its lowest day, 100 its highest
8-year range: 2.2× to 37.9×
Peer median: 8.1×

Collegium Pharmaceutical's price to free cash flow is 2.3× as of Oct 23, 2026.

That is below its 8-year median of 5.4×, lower than on 99% of days in the last 8 years.

Over that time it ranged from 2.2× in Oct 2026 to 37.9× in Feb 2020.

The median for 10 large drugmakers of a similar size is 8.1×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.3×	2.2×	5.2×
2025	5.4×	4.1×	6.1×
2024	4.9×	3.3×	5.4×
2023	3.8×	3.0×	10.4×
2022	8.4×	4.8×	11.1×
2021	7.4×	6.2×	10.6×
2020	8.4×	7.8×	37.9×
2019	14.9×	2.7×	15.5×
2018	5.0×	4.5×	10.3×

Against its peers

Companies in Drug Manufacturers - General nearest Collegium Pharmaceutical's size, closest first, today.

Company	Price to free cash flow
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	13.8×
AMPHAmphastar Pharmaceuticals	7.0×
ARVNArvinas	n/m
OMEROmeros	n/m
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
Peer median	8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Collegium Pharmaceutical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.